Compare › liraglutide vs tirzepatide
liraglutide vs tirzepatide
Both liraglutide and tirzepatide are approved in the US, so the useful differences between them are which conditions each is approved for and what is still under study. liraglutide has 290 trials on file here and tirzepatide 143, which is a rough measure of how far each programme has been pushed.
A side-by-side of what the public record holds on each: regulatory status in the US and EU, how much trial work is running, and which conditions each is being studied in. No efficacy comparison: head-to-head claims belong to the trials that made them, not to us.
| liraglutide | tirzepatide | |
|---|---|---|
| Status | marketed | marketed |
| Target | GLP-1 | GIP/GLP-1 |
| Route | SC | SC |
| Sponsor | Novo Nordisk | Eli Lilly |
| US brand names | LIRAGLUTIDE, SAXENDA, VICTOZA, XULTOPHY 100/3.6 | MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN, ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPEN |
| First FDA approval | 2010-01-25 | 2022-05-13 |
| EU authorisation | Saxenda, Victoza, Xultophy | Mounjaro |
| FDA actions on file | 77 | 27 |
| Active trials | 17 | 99 |
| Active phase 3 | 2 | 23 |
| Participants enrolled | 2,721 | 43,878 |
| Results scheduled | 3 | 35 |
| Supply records | 11 | 0 |
Where they are being studied
Both: Atrial fibrillation; Cardiovascular disease; Diabetes (unspecified); Heart failure; Hypertension; MASH / NAFLD; Metabolic syndrome; Obesity & overweight; Obstructive sleep apnea; Osteoarthritis; Polycystic ovary syndrome; Prediabetes; Psychiatric conditions; Substance use; Type 1 diabetes; Type 2 diabetes
liraglutide only: Diabetic kidney disease; Neurodegenerative disease
tirzepatide only: Alcohol use disorder; Cancer; Chronic kidney disease